Literature DB >> 11343774

Co-existence of alternative forms of 8q gain in cytogenetic clones of three patients with acute myeloid leukemia, pointing to 8q22 approximately 8qter as a region of biologic significance.

J R Batanian1, E Ma, Y Huang, B Gadre.   

Abstract

Clonal trisomy 8 chromosome abnormalities can be detected in 15% of patients with acute myeloid leukemia (AML). The most common form of change is complete gain of the whole chromosome 8, followed by partial gains in unbalanced forms. The biologic consequences of trisomy 8 remain unclear, but a gene dosage effect is suspected. We report on three patients with AML who had alternative forms of chromosome 8 gain in their bone marrow cells. The partial gains resulted from a breakpoint in the chromosome band 8q22. This indicates that the region 8q22 to 8qter may be of particular pathogenetic importance.

Entities:  

Mesh:

Year:  2001        PMID: 11343774     DOI: 10.1016/s0165-4608(00)00385-x

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression.

Authors:  Melanie J McConnell; Nathalie Chevallier; Windy Berkofsky-Fessler; Jena M Giltnane; Rupal B Malani; Louis M Staudt; Jonathan D Licht
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

2.  Computer aided analysis of additional chromosome aberrations in Philadelphia chromosome positive acute lymphoblastic leukaemia using a simplified computer readable cytogenetic notation.

Authors:  Jutta Bradtke; Harald Balz; Christa Fonatsch; Barbara Heinze; Anna Jauch; Brigitte Mohr; Claudia Schoch; Harald Rieder
Journal:  BMC Bioinformatics       Date:  2003-01-28       Impact factor: 3.169

Review 3.  Hypertension-related, calcium-regulated gene (HCaRG/COMMD5) and kidney diseases: HCaRG accelerates tubular repair.

Authors:  Hiroyuki Matsuda; Pavel Hamet; Johanne Tremblay
Journal:  J Nephrol       Date:  2014-02-11       Impact factor: 3.902

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.